PH30305A - Improved meningococcal polysaccharide conjugate vaccine - Google Patents

Improved meningococcal polysaccharide conjugate vaccine

Info

Publication number
PH30305A
PH30305A PH41724A PH41724A PH30305A PH 30305 A PH30305 A PH 30305A PH 41724 A PH41724 A PH 41724A PH 41724 A PH41724 A PH 41724A PH 30305 A PH30305 A PH 30305A
Authority
PH
Philippines
Prior art keywords
conjugate vaccine
polysaccharide conjugate
meningococcal polysaccharide
improved
improved meningococcal
Prior art date
Application number
PH41724A
Other languages
English (en)
Inventor
Harold J Jennings
Francis Michon
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Publication of PH30305A publication Critical patent/PH30305A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PH41724A 1989-12-14 1990-12-14 Improved meningococcal polysaccharide conjugate vaccine PH30305A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44819589A 1989-12-14 1989-12-14

Publications (1)

Publication Number Publication Date
PH30305A true PH30305A (en) 1997-02-20

Family

ID=23779371

Family Applications (1)

Application Number Title Priority Date Filing Date
PH41724A PH30305A (en) 1989-12-14 1990-12-14 Improved meningococcal polysaccharide conjugate vaccine

Country Status (30)

Country Link
US (3) US5576002A (fi)
EP (1) EP0504202B1 (fi)
JP (1) JP2637845B2 (fi)
KR (1) KR0158436B1 (fi)
CN (4) CN1049223C (fi)
AR (1) AR243934A1 (fi)
AT (1) ATE121947T1 (fi)
AU (1) AU641715B2 (fi)
BR (1) BR9007917A (fi)
CA (1) CA2071811C (fi)
CZ (1) CZ283530B6 (fi)
DE (1) DE69019164T2 (fi)
DK (1) DK0504202T3 (fi)
ES (1) ES2071288T3 (fi)
FI (2) FI104539B (fi)
HR (1) HRP920872A2 (fi)
HU (2) HU9201966D0 (fi)
IE (1) IE68414B1 (fi)
IL (1) IL96676A (fi)
IN (1) IN171747B (fi)
NO (2) NO305275B1 (fi)
NZ (1) NZ236471A (fi)
PH (1) PH30305A (fi)
PL (2) PL166659B1 (fi)
RO (1) RO111416B1 (fi)
RU (1) RU2105568C1 (fi)
SI (1) SI20008B (fi)
WO (1) WO1991008772A1 (fi)
YU (1) YU24391A (fi)
ZA (1) ZA9010065B (fi)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648241A (en) * 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
AU641715B2 (en) * 1989-12-14 1993-09-30 National Research Council Of Canada Improved meningococcal polysaccharide conjugate vaccine
ATE203167T1 (de) * 1992-09-24 2001-08-15 Brigham & Womens Hospital Gruppe b streptococcus typ ii und typ v polysaccharid-protein konjugate als impfstoffe
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
EP1090642B8 (en) * 1995-06-07 2010-08-11 GlaxoSmithKline Biologicals s.a. Vaccines comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
ZA97248B (en) * 1996-01-18 1997-07-18 Rohm & Haas Method for identifying and quantifying polymers utilizing immunoassay techniques
PT939647E (pt) 1996-08-27 2002-04-29 Chiron Corp Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos
CA2264585C (en) 1996-08-27 2005-06-14 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
US6426074B1 (en) * 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US6413520B1 (en) 1997-06-24 2002-07-02 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
ATE421527T1 (de) 1997-08-27 2009-02-15 Novartis Vaccines & Diagnostic Molekular-mimetika von meningokokkus b epitopen
ES2346022T3 (es) 1997-12-23 2010-10-07 Baxter Healthcare S.A. Procedimiento para la extraccion y el aislamiento de polisacaridos capsulares bacterianos para su uso como vacunas o ligandos a proteinas como vacunas de conjugados.
CA2340692A1 (en) * 1998-08-19 2000-03-02 North American Vaccine, Inc. Immunogenic .beta.-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6518037B2 (en) * 1999-11-12 2003-02-11 University Of Iowa Research Foundation Two-component system that controls bacterial membrane synthesis
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
WO2002083711A2 (en) 2001-04-17 2002-10-24 Chiron Corporation Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
CA2480389C (en) * 2002-03-26 2012-10-09 Chiron Srl Modified saccharides having improved stability in water
WO2004089407A2 (en) * 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
WO2005016974A1 (en) 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
KR20070060069A (ko) 2004-06-23 2007-06-12 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 다당류 유도체 및 면역반응의 유도에서의 용도
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
ES2750243T3 (es) 2005-06-27 2020-03-25 Glaxosmithkline Biologicals Sa Composición de vacuna que comprende polisacáridos capsulares naturales conjugados de N. Meningitidis
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
EP1872791A1 (en) 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
US20100189740A1 (en) * 2007-06-20 2010-07-29 Francis Michon Modified polysaccharides for conjugate vaccines
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
EP2387417B1 (en) 2009-01-16 2016-05-11 University of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal salmonella
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
EP2752403A1 (de) * 2013-01-08 2014-07-09 Sika Technology AG Amin für emissionsarme Epoxidharz-Produkte
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
CA3030974A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US10183070B2 (en) * 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
AU641715B2 (en) * 1989-12-14 1993-09-30 National Research Council Of Canada Improved meningococcal polysaccharide conjugate vaccine

Also Published As

Publication number Publication date
CN1049223C (zh) 2000-02-09
US5576002A (en) 1996-11-19
WO1991008772A1 (en) 1991-06-27
HUT64480A (en) 1994-01-28
ES2071288T3 (es) 1995-06-16
IE68414B1 (en) 1996-06-12
IE904513A1 (en) 1991-06-19
AR243934A1 (es) 1993-09-30
RU2105568C1 (ru) 1998-02-27
NO973311L (no) 1992-08-14
CN1036522C (zh) 1997-11-26
PL166659B1 (pl) 1995-06-30
ZA9010065B (en) 1992-02-26
AU6898791A (en) 1991-07-18
IL96676A (en) 1996-09-12
HU9201966D0 (en) 1992-10-28
NO307835B1 (no) 2000-06-05
FI19991917A (fi) 1999-09-09
PL166035B1 (pl) 1995-03-31
YU24391A (sh) 1995-12-04
PL288271A1 (en) 1991-12-16
CN1100428A (zh) 1995-03-22
CN1055541A (zh) 1991-10-23
JP2637845B2 (ja) 1997-08-06
JPH05505392A (ja) 1993-08-12
HRP920872A2 (en) 1997-06-30
DK0504202T3 (da) 1995-10-02
NO305275B1 (no) 1999-05-03
NO922316L (no) 1992-08-14
HU218146B (hu) 2000-06-28
FI922737A0 (fi) 1992-06-12
NO973311D0 (no) 1997-07-17
SI20008B (en) 2001-02-28
FI104539B (fi) 2000-02-29
RO111416B1 (ro) 1996-10-31
NO922316D0 (no) 1992-06-12
CZ283530B6 (cs) 1998-04-15
BR9007917A (pt) 1992-10-20
IL96676A0 (en) 1991-09-16
NZ236471A (en) 1992-10-28
AU641715B2 (en) 1993-09-30
DE69019164T2 (de) 1995-09-07
CN1096516A (zh) 1994-12-21
ATE121947T1 (de) 1995-05-15
US5683699A (en) 1997-11-04
CA2071811A1 (en) 1991-06-15
EP0504202B1 (en) 1995-05-03
CZ628490A3 (en) 1997-12-17
KR0158436B1 (ko) 1998-12-01
EP0504202A1 (en) 1992-09-23
DE69019164D1 (de) 1995-06-08
SI20008A (sl) 2000-02-29
IN171747B (fi) 1992-12-26
CN1072506C (zh) 2001-10-10
CN1036504C (zh) 1997-11-26
US5902586A (en) 1999-05-11
CA2071811C (en) 2003-11-04
CN1100656A (zh) 1995-03-29

Similar Documents

Publication Publication Date Title
AR243934A1 (es) Un metodo para obtener n-alcanoil(c4-c8)gbmp a partir de gbmp n-desacetilado y metodo para preparar conjugados de proteinas inmunologicas con dicho producto n-desacetilado.
GB8907914D0 (en) Vaccine preparation
HU896283D0 (en) Colon-selective, peroral medical preparation
GB8924438D0 (en) Vaccine composition
EP0262876A3 (en) Nucleoside-phospholipid conjugate
HUP9802664A3 (en) Modified meningococcal polysaccharide conjugate vaccines and modified polysaccharides
EP0454735A4 (en) Vaccine composition
GB8921470D0 (en) Vaccines
EP0468714A3 (en) Peptide-polysaccharide-protein conjugate vaccines
PT86286A (en) Conjugate vaccine
AU1118888A (en) Conjugate malaria vaccine
GB9017370D0 (en) Tuberculosis vaccine
GB8918689D0 (en) 25/15 vaccine
EP0504136A4 (en) Tolerogenic immunoglobulin-protein conjugates
GR3019065T3 (en) Vaccine Composition
GB2232681B (en) Nitro-p-phenylenediamine derivatives
ZA907863B (en) Vaccine conjugate
GB8912496D0 (en) Vaccines
ZA92536B (en) Pneumococcal polysaccharide conjugate vaccine
PL346645A1 (en) IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
EP0453452A4 (en) Vaccine
ZA88792B (en) Conjugate malaria vaccine
GB8922651D0 (en) Vaccine
ZA90766B (en) Vaccine composition
GB8628286D0 (en) Polymer-peptide conjugate